Drug Profile
Research programme: levodopa-induced dyskinesia therapeutic - MentiNova
Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator MentiNova
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Drug-induced dyskinesia
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA (PO)
- 08 Dec 2015 Development is ongoing in USA